ADMA Biologics, Inc.
ADMA
$6.58
$0.0250.38%
| Weiss Ratings | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.46 | |||
| Price History | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.65% | |||
| 30-Day Total Return | 2.99% | |||
| 60-Day Total Return | 19.46% | |||
| 90-Day Total Return | 47.62% | |||
| Year to Date Total Return | 36.26% | |||
| 1-Year Total Return | 87.88% | |||
| 2-Year Total Return | 222.92% | |||
| 3-Year Total Return | 233.33% | |||
| 5-Year Total Return | 31.91% | |||
| 52-Week High % Change | -4.73% | |||
| 52-Week Low % Change | 110.46% | |||
| Price | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.76 | |||
| 52-Week Low Price | $3.06 | |||
| 52-Week Low Price (Date) | Oct 23, 2023 | |||
| 52-Week High Price (Date) | Mar 28, 2024 | |||
| Valuation | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.45B | |||
| Enterprise Value | 1.54B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.13 | |||
| Earnings Per Share Growth | -61.61% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 5.49 | |||
| Price/Book (Q) | 10.48 | |||
| Enterprise Value/Revenue (TTM) | 6.13 | |||
| Price | $6.20 | |||
| Enterprise Value/EBITDA (TTM) | 47.31 | |||
| Enterprise Value/EBIT | 62.97 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 225.97M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 201 478 5552 | |||
| Address | 465 State Route 17 Ramsey, NJ 07446 | |||
| Website | www.admabiologics.com | |||
| Country | United States | |||
| Year Founded | 2004 | |||
| Profitability | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 9.73% | |||
| Profit Margin | -10.93% | |||
| Management Effectiveness | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 4.64% | |||
| Return on Equity | -- | |||
| Income Statement | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 258.22M | |||
| Total Revenue (TTM) | 258.22M | |||
| Revenue Per Share | $1.14 | |||
| Gross Profit (TTM) | 91.04M | |||
| EBITDA (TTM) | 33.46M | |||
| EBIT (TTM) | 25.13M | |||
| Net Income (TTM) | -28.24M | |||
| Net Income Avl. to Common (TTM) | -28.24M | |||
| Total Revenue Growth (Q YOY) | 47.86% | |||
| Earnings Growth (Q YOY) | -44.25% | |||
| EPS Diluted (TTM) | -0.13 | |||
| EPS Diluted Growth (Q YOY) | -30.59% | |||
| Balance Sheet | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 51.35M | |||
| Cash Per Share (Q) | $0.23 | |||
| Total Current Assets (Q) | 257.01M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 135.21M | |||
| Current Ratio (Q) | 5.160 | |||
| Book Value Per Share (Q) | $0.60 | |||
| Total Assets (Q) | 329.18M | |||
| Total Current Liabilities (Q) | 49.81M | |||
| Total Debt (Q) | 141.42M | |||
| Total Liabilities (Q) | 193.98M | |||
| Total Common Equity (Q) | 135.21M | |||
| Cash Flow | ADMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -4.98M | |||
| Cash from Financing (TTM) | -38.99M | |||
| Net Change in Cash (TTM) | -35.17M | |||
| Levered Free Cash Flow (TTM) | 816.20K | |||
| Cash from Operations (TTM) | 8.80M | |||
